IDEA4RC FHIR Implementation Guide
0.1.0 - CI Build 150

IDEA4RC FHIR Implementation Guide, published by IDEA4RC Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/idea4rc/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 IDEA4RC FHIR IG - Home Page
... 2 IDEA4RC Model Overview
... 3 IDEA4RC Detailed ERD Model
... 4 IDEA4RC Logical Models
... 5 Useful Downloads
... 6 Condition-secondaryCancer-eu-i4rc Relationships
... 7 Encounter-eu-i4rc Relationships
... 8 Condition-primaryCancer-eu-i4rc Relationships
... 9 sarcoma-cancer-stage-group Relationships
... 10 hn-cancer-stage-group Relationships
... 11 episodeOfCare-eu-i4rc Relationships
... 12 MedicationAdministration-eu-i4rc Relationships
... 13 Subject Relationships
... 14 PatientFollowUp Relationships
... 15 EpisodeEvent Relationships
... 16 HospitalPatientRecords Relationships
... 17 CancerEpisode Relationships
... 18 AdverseEvent Relationships
... 19 GeneticTestExpression Relationships
... 20 Surgery Relationships
... 21 Radiotherapy Relationships
... 22 Artifacts Summary
.... 22.1 Adverse Event
.... 22.2 Cancer Episode
.... 22.3 Clinical Stage
.... 22.4 Diagnosis
.... 22.5 Disease Extent
.... 22.6 Drugs For Treatments
.... 22.7 Episode Event
.... 22.8 Genetic Test Expression
.... 22.9 Hospital Patient Records
.... 22.10 IsolatedLimbPerfusion
.... 22.11 OverallTreatmentResponse
.... 22.12 Pathological Stage
.... 22.13 Patient
.... 22.14 Patient Follow-Up
.... 22.15 Radiotherapy
.... 22.16 RegionalDeepHyperthemia
.... 22.17 Surgery
.... 22.18 Systemic Treatment
.... 22.19 Adverse Event Model to this guide Map
.... 22.20 Cancer Episode Model to this guide Map
.... 22.21 Clinical Stage Model to this guide Map
.... 22.22 Diagnosis to this guide Map
.... 22.23 Disease Extent Model to this guide Map
.... 22.24 Drugs For Treatments Model to this guide Map
.... 22.25 Episode Event Model to this guide Map
.... 22.26 Genetic Test Expression Model to this guide Map
.... 22.27 Hospital Patient Records Model to this guide Map
.... 22.28 Isolated Limb Perfusion Model to this guide Map
.... 22.29 Overall Treatment Response Model to this guide Map
.... 22.30 Pathological Stage Model to this guide Map
.... 22.31 Patient (Subject) Model to this guide Map
.... 22.32 Patient Follow up Model to this guide Map
.... 22.33 Radiotherapy Model to this guide Map
.... 22.34 Regional Deep Hyperthemia Model to this guide Map
.... 22.35 Surgery Model to this guide Map
.... 22.36 Systemic Treatment Model to this guide Map
.... 22.37 Observation: Alcohol use
.... 22.38 Observation: Cancer Treatment
.... 22.39 Observation: Charlson Comorbidity Index
.... 22.40 Observation: Comorbidities
.... 22.41 Observation: ECOG Performance Status
.... 22.42 Observation: Karnofsky Performance Status
.... 22.43 Observation: Occurrence of the other cancer
.... 22.44 Observation: Tobacco use
.... 22.45 Patient: IDEA4RC
.... 22.46 Condition: Primary Cancer
.... 22.47 Observation: Diagnosis details
.... 22.48 Observation: Head Neck Cancer Stage Group
.... 22.49 Observation: Localized Category (Stage, Sarcoma)
.... 22.50 Observation: LocoRegional Category (Stage)
.... 22.51 Observation: Number of tumor nodules
.... 22.52 Observation: Radiological Extra-nodal extension (rENE)
.... 22.53 Observation: Sarcoma Cancer and Disease Extent Stage Group
.... 22.54 Observation: TNM Distant Metastases Category
.... 22.55 Observation: TNM Primary Tumor Category
.... 22.56 Observation: TNM Regional Nodes Category
.... 22.57 Encounter: IDEA4RC
.... 22.58 Observation: date of the last contact
.... 22.59 Observation: Status at the Last Follow Up
.... 22.60 Procedure: Surgery
.... 22.61 Procedure: Radiotherapy
.... 22.62 MedicationAdministration: Chemotherapy
.... 22.63 EpisodeOfCare: IDEA4RC
.... 22.64 AdverseEvent: IDEA4RC
.... 22.65 Bundle: IDEA4RC
.... 22.66 Condition: Metastatic Cancer
.... 22.67 Observation: Genetic Test Expression
.... 22.68 Observation: Overall Treatment
.... 22.69 Observation: test results
.... 22.70 Observation: Tumor Rupture
.... 22.71 Observation: Yes / No assertions
.... 22.72 Procedure: Immaging for Clinical Stage
.... 22.73 Procedure: Other Treatment
.... 22.74 Substance : Other Treatment
.... 22.75 Adaptive
.... 22.76 Body Location Qualifier
.... 22.77 Chemotherapy Timing
.... 22.78 Condition related to resource
.... 22.79 Histology Morphology Behavior
.... 22.80 Laterality Qualifier
.... 22.81 Medication Outcome
.... 22.82 Performed Timing
.... 22.83 Previous Status
.... 22.84 Race Extension
.... 22.85 Radiotherapy Dose Delivered To Volume Extension
.... 22.86 Radiotherapy Energy or Isotope
.... 22.87 Radiotherapy Modality And Technique Extension
.... 22.88 Radiotherapy Modality Extension
.... 22.89 Radiotherapy Number of Sessions Extension
.... 22.90 Radiotherapy Setting
.... 22.91 Radiotherapy Technique Extension
.... 22.92 Relapse Type
.... 22.93 Same custodian flag
.... 22.94 Same Hospital
.... 22.95 Total High Dose Delivered
.... 22.96 Immaging Body sites
.... 22.97 Immaging Clinical Stage
.... 22.98 Immaging Clinical Stage Metastasis
.... 22.99 Immaging Clinical Stage Neck
.... 22.100 Immaging Clinical Stage Primary Site
.... 22.101 Adverse Event Type
.... 22.102 Affected Organs (surgery)
.... 22.103 Alcohol Usage Status: Athena
.... 22.104 Alcohol Usage Status: SNOMED CT
.... 22.105 Antineoplastic and immunostimulating agents
.... 22.106 Beam Quality
.... 22.107 Body site qualifier
.... 22.108 Calculated|Estimated
.... 22.109 Cancer Diagnosis: Athena
.... 22.110 Cancer histology behaviour: Athena
.... 22.111 Cancer histology subgroup: Athena
.... 22.112 Cancer histology: Athena
.... 22.113 Cancer site: Athena
.... 22.114 Cancer Stage Grading: Athena
.... 22.115 Cancer Stage Group Value Clinical: Athena
.... 22.116 Cancer Stage Group Value Pathological: Athena
.... 22.117 Cancer Stage Group Value: Athena
.... 22.118 Cancer Stage Group: Athena
.... 22.119 Chemotherapy cumulative dose units
.... 22.120 Chemotherapy Info
.... 22.121 Clinical TNM Primary Tumor Category Value Set
.... 22.122 Coded test results: Athena.
.... 22.123 Comorbidities: Athena
.... 22.124 Comorbidities: SNOMED
.... 22.125 Country: athena
.... 22.126 Current Smoking Status: Athena
.... 22.127 Disease Status: Athena
.... 22.128 Drugs for Systemic Treatment
.... 22.129 Drugs for Treatments
.... 22.130 ECOG Performance Status
.... 22.131 Event Type
.... 22.132 Extranodal Extension
.... 22.133 Gender: Athena
.... 22.134 Genetic test expression
.... 22.135 Genetic Tests performed (Yes/no/Unk)
.... 22.136 Genito urinary subsite: Athena
.... 22.137 Hypopharynx subsite: Athena
.... 22.138 Hypopharynx subsite: Snomed CT
.... 22.139 Intra abdominal subsite: Athena
.... 22.140 Intra thoracic subsite : Athena
.... 22.141 Larynx subsite: Athena
.... 22.142 Larynx subsite: Snomed CT
.... 22.143 Lip subsite: Athena
.... 22.144 Lip subsite: Snomed CT
.... 22.145 Margins After Surgery
.... 22.146 Metastatis: Athena
.... 22.147 Mitotic Index: Athena.
.... 22.148 Nasal cavity and paranasal sinuses subsite: Athena
.... 22.149 Nasal cavity and paranasal sinuses subsite: Snomed CT
.... 22.150 Nasopharynx subsite: Athena
.... 22.151 Nasopharynx subsite: Snomed CT
.... 22.152 Not Performed|Unknown
.... 22.153 Observation Codes for Distant Metastases Category
.... 22.154 Observation Codes for Primary Tumor Category
.... 22.155 Observation Codes for Regional Node Category
.... 22.156 Occurrence of other cancer
.... 22.157 Oral cavity subsite: Athena
.... 22.158 Oral cavity subsite: Snomed CT
.... 22.159 Oropharynx subsite: Athena
.... 22.160 Oropharynx subsite: Snomed CT
.... 22.161 Other Treatment Procedure Type
.... 22.162 Pathological M
.... 22.163 Pathological N
.... 22.164 Pathological T
.... 22.165 Pathological TNM Primary Tumor Category Value Set
.... 22.166 Positive-Negative-No Test: Athena
.... 22.167 Positive-Negative-No Test: Athena
.... 22.168 Race
.... 22.169 Radiotherapy Device Type
.... 22.170 Radiotherapy Site Laterality Qualifier
.... 22.171 Radiotherapy Sites
.... 22.172 Re-irradiation reason
.... 22.173 Reason to End Treatment
.... 22.174 Regimen
.... 22.175 Sarcoma Staging: localized disease
.... 22.176 Setting Radiotherapy
.... 22.177 Simple measures
.... 22.178 Site of metastasis
.... 22.179 Site rare (IDEA4RC)
.... 22.180 Site: Athena
.... 22.181 Smoking Status: LOINC
.... 22.182 Staging: loco-regional category
.... 22.183 Status at the Last Follow Up
.... 22.184 Subsites: Athena
.... 22.185 Subsites: SNOMED CT
.... 22.186 Surgery Complication
.... 22.187 Surgery Intention
.... 22.188 Surgery Location Qualifier
.... 22.189 Surgery Outcome
.... 22.190 Surgery Site Laterality Qualifier
.... 22.191 Surgery Sites
.... 22.192 Surgical Complications
.... 22.193 Surgical Procedure Category
.... 22.194 Surgical Procedure Type
.... 22.195 TNM Distant Metastases Category Value Set (Clinical)
.... 22.196 TNM Distant Metastases Category Value Set (Pathological)
.... 22.197 TNM Primary Tumor Category Value Set
.... 22.198 TNM Regional Nodes Category Value Set (Clinical)
.... 22.199 TNM Regional Nodes Category Value Set (Pathological)
.... 22.200 Tobacco Product
.... 22.201 Treatment completed as planned
.... 22.202 Treatment Response
.... 22.203 Treatment Setting
.... 22.204 Treatment Technique
.... 22.205 Trunk wall subsite: Athena
.... 22.206 Type of Biopsy
.... 22.207 Type of Diagnosis
.... 22.208 Type of surgical approach
.... 22.209 Type of Systemic Treatment
.... 22.210 Type of Treatment
.... 22.211 Types of Yes/No observations
.... 22.212 Upper and Lower limbs subsite: Athena
.... 22.213 Yes-No-Unk: Athena
.... 22.214 IDEA4RC Body Topography Code System
.... 22.215 IDEA4RC Cancer Diagnosis Code System
.... 22.216 IDEA4RC Code System
.... 22.217 IDEA4RC Vocabulary Code System
.... 22.218 Genetic Test to this guide Map
.... 22.219 HN Stage Model to this guide Map
.... 22.220 Other Treatment to this guide Map
.... 22.221 Stage Model to this guide Map
.... 22.222 Actor: Head and Neck
.... 22.223 Actor: Sarcoma
.... 22.224 Condition: Grade 2 tumor with several body sites and evidences
.... 22.225 Condition: Metastasis bone and pleura
.... 22.226 Condition: NOT CLEAR WHAT IT REPRESENTS..TO BE DISCUSSED
.... 22.227 Condition: Stable Disease
.... 22.228 encounter-id-14
.... 22.229 EpisodeOfCare
.... 22.230 GOFSH-GENERATED-id-28
.... 22.231 GOFSH-GENERATED-id-30
.... 22.232 GOFSH-GENERATED-id-36
.... 22.233 Observation: Alcohol use
.... 22.234 Observation: BMI
.... 22.235 Observation: C reactive protein Positive
.... 22.236 Observation: Charlson Comorbidity Index
.... 22.237 Observation: comorbidity
.... 22.238 Observation: date of the last contact
.... 22.239 Observation: Diagnosis
.... 22.240 Observation: Dimension of Tumor
.... 22.241 Observation: Distant metastases clinical M1
.... 22.242 Observation: Distant metastases pathology M1
.... 22.243 Observation: ECOG Performance Status score
.... 22.244 Observation: Epstein Barr virus DNA Negative
.... 22.245 Observation: gene Mutation Analysis Performed yes
.... 22.246 Observation: Human papilloma virus Negative
.... 22.247 Observation: immunohiostochemestry analysis performed
.... 22.248 Observation: Karnofsky Performance Status score
.... 22.249 Observation: Number of mitoses per HPF
.... 22.250 Observation: Occurrence of other Cancer: Hamartoma
.... 22.251 Observation: Primary tumor clinical T0
.... 22.252 Observation: Primary tumor pathological T0
.... 22.253 Observation: Radiological Extra-nodal extension
.... 22.254 Observation: Regional lymph nodes Clinical N1
.... 22.255 Observation: Regional lymph nodes pathology N3b
.... 22.256 Observation: Surgery treatment occurred
.... 22.257 Observation: TNM clinical stage grouping
.... 22.258 Observation: TNM pathology stage grouping
.... 22.259 Observation: Tobacco use panel
.... 22.260 Patient: race extension
.... 22.261 Procedure: Isolated limb perfusion